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Abstract
Introduction. Arterial hypertension is the most frequent modifiable risk factor for cardiovascular disease and premature 
mortality globally. Availability of novel antihypertensive agents with unique pharmacological characteristics improves 
the efficacy and safety of antihypertensive therapy. The aim of the ALMONDS survey was to identify the attitude of Po-
lish medical professionals towards novel pharmacological agents used in the therapy of hypertension. In particular, we 
sought to investigate the views regarding the “class effect” for antihypertensive agents.
Material and methods. The study was conducted using a standardized survey, which was filled in by 784 specialists or 
trainees in cardiology, internal medicine, family medicine, and diabetology. The letter form and anonymity of the survey 
allowed to maximize the reliability of the collected data.
Results. The majority of the study group were females 46-60 years of age. A substantial proportion of the physicians 
specialized in internal medicine and had more than 20 years of professional experience. The management was mostly 
guided by the Polish Society of Hypertension (PTNT) guidelines or the European Society of Hypertension (ESH)/European 
Society of Cardiology (ESC) guidelines. In patients with hypertension and coronary artery disease, the most commonly 
chosen drug treatment included a beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor or an ACE inhibitor 
and a vasodilating beta-blocker. The latter combination was also selected most frequently in patients with hypertension 
and heart failure. In women in reproductive age, a vasodilating beta-blocker and a calcium antagonist were selected most 
frequently, while a combination of nebivolol and zofenopril was indicated as the best in young men with hyperkinetic 
circulation. In patients with resistant hypertension, the most frequently chosen regimen included furosemide, amlodipine, 
zofenopril, and nebivolol. Another popular combination included torasemide, lercanidipine, telmisartan, and carvedilol.
Conclusions. The results of our study indicate that Polish medical professionals have clear preferences regarding spe-
cific pharmacological agents within drug classes. Vasodilating agents are preferred among beta blockers, newer agents 
among ACE inhibitors, dihydropyridines among calcium antagonists, and loop diuretics among diuretics. This attitude is 
generally consistent with the 2015 PTNT guidelines.
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Introduction
Hypertension is the most common modifiable risk factor for 
cardiovascular disease globally, responsible for 7.6 million 
premature deaths (in subjects < 69 years of age), or 13.5% 
of all deaths [1]. Global prevalence of hypertension has been 
estimated at 970 million, including 330 million in the develo-
ped countries [2]. The NATPOL 2011 epidemiological study, 
evaluating hypertension and other cardiovascular risk factors 
in Poland, indicated that also in our country, hypertension 
is the second most common cardiovascular risk factor after 
hyperlipidaemia, present in 32% (10.5 million) adult Poles 
[3]. Despite a two-fold increase in the proportion of patients 
with controlled hypertension found in 2011 compared to 
2002, still about 30% of hypertensive subjects (3.1 million) 
are not aware of this diagnosis. At the same time, the Moni-
toring of Trends and Determinants in Cardiovascular Disease 
(MONICA) project by the World Health Organization showed 
that the reduction in cardiovascular mortality observed sin-
ce mid-1980s may be attributed in two thirds to better risk 
factor control and reduced disease incidence, and in only 
one third to more effective treatment [4].
Adequate blood pressure control is often a challenge in 
clinical practice. This is related to patient non-compliance, 
the most common cause of pseudoresistance to multi-drug 
treatment [5], and physician non-adherence to the recom-
mendations regarding antihypertensive drug therapy [6]. 
Results of large randomized clinical trials published in the 
recent years created new opportunities for individualizing 
the management of hypertension using specific antihy-
pertensive drugs within drug classes or their fixed-dose 
combinations. Currently available scientific data were 
reflected in the new guidelines on the management of hy-
pertension, developed by the experts of the Polish Society 
of Hypertension (PTNT, Polskie Towarzystwo Nadciśnienia 
Tętniczego) and released in May 2015 at a conference of 
the “Nadciśnienie Tętnicze” journal [7].
The aim of the ALMONDS (Are ALl pills equal within the 
MajOr hypotensive Drug classeS?) survey was to identify 
the attitude of Polish physicians toward new drugs used 
in the treatment of hypertension. Importantly, we wanted 
to learn the opinion of Polish medical professionals regar-
ding the current principles of antihypertensive therapy, in 
particular the class effect for antihypertensive agents, or 
a claim that all drugs are equal within a given antihyper-
tensive drug class.
Material and methods
The study was performed using a standardized survey 
approach. For this purpose, we used a questionnaire 
that was sent to the participating physicians along with 
an introductory letter prepared by the study authors. The 
individual survey approach allowed the participants to 
choose answers to particular items among the proposed 
categories (multiple choice questionnaire), which allowed 
comparing results between the participants. The answers 
provided were entered to an electronic database and analy-
sed quantitatively using statistical methods. The advantage 
of the approach used was an avoidance of the interviewer 
effect, i.e. a purposeful or unintended influence of the 
interviewer/researcher on the answers given, increasing 
reliability of the results. According to the Personal Data 
Protection Act, information obtained from the respondents 
was kept confidential and used only to compile summary 
statistics that included no data that might allow identifica-
tion of the respondent.
The study protocol was submitted to the Bioethics 
Committee at the Medical University of Warsaw which had 
no objections to both the content of the questionnaire and 
the study concept.
The study was conducted in the period from July to 
September 2015 and covered the whole country. Overall 
784 specialists or trainees in cardiology, internal medicine, 
diabetology, and family medicine participated in the study. 
The study results regarding the physicians’ attitude towards 
new antihypertensive agents were reported in relation to 
gender, age, place of work, specialization, professional 
experience, and practice settings. To report medical pro-
fessionals’ answers in relation to their place of work, the 
whole country Poland was divided into four areas as shown 
on Figure 1.
Figure 1. Place of work of the participating physicians
VOIVODESHIPS
Silesian 15.6%
Greater Poland 9.7%
Mazovian 8.9%
Lodz 7.9%
Lublin 7.6%
Subcarpathian 7.1%
Lesser Poland 6.9%
Holy Cross 5.7%
Lower Silesian 5.3%
Podlaskie 4.8%
Pomeranian 4.8%
Opole 3.9%
Warmian-Masurian 3.6%
West Pomeranian 3.6%
Kuyavian-Pomeranian 3.0%
Lubusz 1.6%
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Results
Study group characteristics
More than half (50.7%) of the participating physicians were 
aged 46–60 years, and 46% of the study participants were 
men. Three voivodeships with the highest number of partici-
pants were Silesian, Greater Poland, and Mazovian (15.6%, 
9.7%, and 8.9% of participating physicians, respectively). 
Internal medicine specialists comprised 46.2% of the stu-
dy group, family medicine specialists comprised 26.9%, 
cardiologists comprised 25.8%, and diabetes specialists 
comprised 1.1%. Nearly half of the participants (47.3%) had 
more than 20 years of professional experience, followed 
by physicians with 11-20 years of professional experience 
(36.6%), and the smallest group were physicians with less 
than 10 years of professional experience (16.1%). Three 
fourths (74.6%), of the participants practiced in outpatient 
settings and one fourth (25.4%) practiced in hospital 
settings. The demographic, geographic, and professional 
characteristics of the study population are shown in Table 1 
and Figure 1.
Sources of knowledge underlying  
management decisions  
of Polish medical professionals
Participating physicians declared that their decisions regar-
ding the management of hypertensive patients were mostly 
based on the PTNT guidelines (57.3% of women and 42.2% 
of men) and the European Society of Hypertension (ESH)/
European Society of Cardiology (ESC) (24.3% of women and 
32.0% of men). Other indicated sources included lectures 
and courses by Polish experts (12.2% of women and 15% of 
men), and personal practice with many years of experience 
(6.2% of women and 10.8% of men). Physicians ≥ 30 years 
of age mostly indicated the PTNT guidelines (46.9–56.7% 
of the respondents in various age groups), while physicians 
< 29 years of age mostly indicated the European guidelines 
(39.3%). Cardiologists were the only group that mostly made 
decisions guided by the European guidelines (53.6%), while 
the PTNT guidelines were most popular source of knowledge 
for internal medicine, family medicine, and diabetes spe-
cialists (53.6–59.1%), as shown in Figure 2.
When planning antihypertensive therapy, hospital 
specialists were more frequently guided by the European 
guidelines (49.2%), while specialists practicing in outpa-
tient settings were mostly guided by the PTNT guidelines 
(54.4%). None of the participants reported being guided 
by the Joint National Committee (JNC) guidelines when 
making management decisions.
Table 1. Characteristics of the surveyed physician population
Parameter Percentage [%]
Gender
Men
Women
46
54
Age [years]
< 29
30–45
46–60
> 61
3.7
37.4
50.7
8.2
Specialization
Internal medicine
Family medicine
Cardiology
Diabetology
46.2
26.2
25.8
1.1
Professional experience [years]
< 10
10–20
> 20 years
16.1
36.6
47.3
Practice settings
Outpatient
Inpatient
74.6
25.4
Figure 2. Sources of knowledge affecting management decisions 
of Polish physicians depending on their specialization; ESH — Eu-
ropean Society of Hypertension; ESC — European Society of Cardio-
logy; PTNT (Polskie Towarzystwo Nadciśnienia Tętniczego) — Polish 
Society of Hypertension
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Goals of antihypertensive therapy
The most important management goal in patients with 
hypertension, declared by both women (72.3%) and men 
(69.4%), was blood pressure reduction to normal values 
or as close to normal values as possible and reduction of 
global cardiovascular risk. Other declared goals included 
protection from such events as myocardial infarction, 
stroke, and death (16.6% of women and 18.7% of men), 
blood pressure reduction to values defined as maximum 
normal (7.1% of women and 18.7% of men), maximum 
blood pressure reduction (3% of women and 4.4% of men), 
and achieving normal 24-hour BP monitoring values (1% 
of women and 2% of men). This response distribution was 
similar in all age groups regardless of the place of work, 
specialization, professional experience, and work settings. 
Diabetologists considered achieving normal 24-hour BP 
monitoring values the most important management goal 
more frequently than other specialists (12.5% vs. 1–1.7% 
among other specialists). Hospital specialists considered 
protection from myocardial infarction, stroke, and death 
the most important management goal more frequently 
than specialists practicing in outpatient settings (21.4% vs. 
15.9%). Declared goals of the management of hypertension 
depending on practice settings are shown in Figure 3.
Management of hypertension  
in special patient populations
When the respondents were asked to select the best regi-
men for patient groups listed below, they were allowed to 
indicate more than one treatment option.
In patients with hypertension and diabetes, the most 
commonly chosen regimen was a combination of an an-
giotensin-converting enzyme (ACE) inhibitor and a calcium 
antagonist (46.7% of women and 50.9% of men), followed 
by an ACE inhibitor and a vasodilating beta-blocker (26.3% 
of women and 25.7% of men). Less frequently chosen com-
binations included an ACE inhibitor and a diuretic (17.4% of 
women and 12.1% of men), an angiotensin receptor blocker 
(ARB) and a calcium antagonist (8.7% of women and 8.4% 
of men), and least frequently an ARB and a diuretic (3% 
of women and 3.5% of men). The combination of an ACE 
inhibitor and a calcium antagonist was most commonly 
chosen by the youngest physicians (< 29 years of age), 
as illustrated in Figure 4. This regimen was also more 
popular among diabetologists (62.5%) and cardiologists 
(55.4%) than among internal medicine specialists (47.1%) 
and family medicine specialists (45.5%). It was also more 
popular among hospital specialists (56.4%) compared to 
those practicing in outpatient settings (46.2%).
In patients with hypertension and established coro-
nary artery disease, the most popular treatment regimen 
was a combination of an ACE inhibitor and a beta-blocker 
(44.7% of women, 41.2% of men) or a vasodilating beta-
-blocker (41.8% of women, 42.9% of men). Much less fre-
quently recommended regimens included an ACE inhibitor 
and a calcium antagonist (7.9% of women and 9% of men), 
an ACE inhibitor and a diuretic (3.9% of women and 4.1% of 
men), and a beta-blocker and a calcium antagonist (3.4% 
of women and 3.8% of men). A combination of an ACE 
inhibitor and a beta-blocker was most commonly chosen 
be physicians < 29 years of age. Management decisions 
Figure 3. Declared goals of the management of hypertension de-
pending on practice settings; BP — blood pressure
Figure 4. Management of hypertension in patients with concomi-
tant diabetes depending on physician’s age; ACE — angiotensin-
-converting enzyme
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in this patient group also showed significant geographical 
variation, as illustrated in Figure 5. A combination of an 
ACE inhibitor and a beta-blocker was not chosen by any 
diabetologist, while it was the most popular combination 
among cardiologists and internal medicine specialists 
(49.7% and 46.3%, respectively). Instead, 50% of diabe-
tologists would choose therapy with an ACE inhibitor and 
a vasodilating beta-blocker.
In patients with hypertension and heart failure, a large 
majority of the surveyed physicians would choose an ACE 
inhibitor and a vasodilating beta-blocker (56.5% of women 
and 63.6% of men), as illustrated in Figure 6. The second 
most commonly chosen treatment option was a combi-
nation of an ACE inhibitor and an aldosterone antagonist 
(28.6% of women and 22% of men). Much fewer physicians 
would choose treatment with an ARB and a diuretic (9.4% 
of women and 7.8% of men) or an ACE inhibitor and a dihy-
dropyridine calcium antagonist (5.7% of women and 5.5% of 
men). Only a small proportion would recommend treatment 
with an ARB and a dihydropyridine calcium antagonist (1.7% 
of women and 2.3% of men). Compared to other specialists, 
diabetologists were much more likely to indicate regimens 
involving a dihydropyridine calcium antagonist or an ARB.
In patients with hypertension and concomitant chronic 
obstructive pulmonary disease (COPD), the most frequ-
ently chosen combination included an ACE inhibitor and 
a calcium antagonist (39% of women and 39.9% of men) 
or an ARB and a calcium antagonist (30.3% of women and 
26.5% of men). Less popular choices included a calcium 
antagonist and a vasodilating beta-blocker (13.2% of wo-
men, 14.9% of men) and an ACE inhibitor and a diuretic 
(13.4% of women, 14.6% of men), while the least com-
monly indicated choice was a combination of an ARB and 
a diuretic (5.5% of women, 6.4% of men). A regimen of an 
ACE inhibitor and a calcium antagonist would be recom-
mended by a half of cardiologists (50.3%), just above one 
third of family physicians (34.7%) and internal medicine 
specialists (34.2%), and only one fourth of diabetologists 
(25%). Instead, diabetologists were more likely to choose 
a combination of a calcium antagonist and a vasodilating 
beta-blocker (25%) or a calcium antagonist and an ARB 
(25%). A combination of an ACE inhibitor and a calcium 
antagonist was also much more popular among hospital 
specialists (52.3%) compared to those practicing in outpa-
tient settings (34.2%), where an equally popular choice was 
a combination of an ARB and a calcium antagonist (32.3%).
Antihypertensive treatment  
in patients with resistant hypertension
In patients with isolated systolic hypertension uncontrolled 
with monotherapy, the most frequently chosen combination 
was a diuretic and a calcium antagonist (36.8% of women 
and 35.2% of men). Quite popular regimens also included 
an ACE inhibitor combined with a diuretic (21.8% of women 
and 27% of men) or a calcium antagonist (20.8% of women 
and 22.6% of men). Less popular but still quite common 
regiments included a vasodilating beta-blocker combined 
with a calcium antagonist (9.5% of women and 9.4% of 
Figure 5. Management of hypertension in patients with concomi-
tant coronary artery disease depending on the place of work; ACE 
— angiotensin-converting enzyme Figure 6. Treatment regimen for hypertension with concomitant 
heart failure depending on physician’ gender; ACE — angiotensin-
-converting enzyme
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men) or an ACE inhibitor (12.0% of women and 6.5% of 
men). Preferred treatment regimens in this patient group 
depending on physician’s age are shown in Figure 7.
In women of reproductive age with hypertension uncon-
trolled with monotherapy, the most commonly indicated 
treatment regimen was a combination of a vasodilating 
beta-blocker and a calcium antagonist (34.9% of women 
and 35.7% of men), followed by a calcium antagonist and 
a centrally acting drug (26.9% of women and 29.6% of 
men). All other possible responses, including any beta-
-blocker and a calcium antagonist, a diuretic and a calcium 
antagonist, and a diuretic and a vasodilating beta-blocker, 
gained a comparable support among the respondents 
(9–14%). However, opinions of the surveyed physicians 
showed some variation depending on the place of work 
and specialization, with the regimen of a calcium antago-
nist and a centrally acting drug being most popular in the 
northwestern part of the country and among diabetologists.
In a young man with hypertension and hyperkinetic 
circulation who is uncontrolled with monotherapy, most re-
spondents would use a regimen of nebivolol and zofenopril 
(77.7% of women and 71.3% of men). Much less frequently 
suggested regimens included bisoprolol and perindopril 
(14.9% of women, 21.4% of men) and carvedilol and ra-
mipril (5.4% of women, 3.8% of men), and only a marginal 
proportion of physicians would recommend metoprolol and 
quinapril or metoprolol XL/CR and trandolapril (0.5–2.3%). 
These trends were seen regardless of the physician age, 
place of work, practice settings, and professional expe-
rience. The only exception were medical professionals 
< 29 years of age who would less frequently choose nebi-
volol and zofenopril (60.7%), and more frequently bisoprolol 
and perindopril (32.1%). Also diabetologists preferred only 
these two combinations in this clinical scenario.
In patients with resistant hypertension who required 
a 4-drug combination (diuretic, calcium antagonist, renin– 
–angiotensin system inhibitor, and beta-blocker), the most 
commonly chosen regimen was a combination of furose-
mide, amlodipine, zofenopril, and nebivolol, indicated by 
46.7% of women and 41.21% of men. The second most 
common regimen included torasemide, lercanidipine, 
telmisartan, and carvedilol and was indicated by 36.5% 
of women and 34% of men. Other possible options were 
indapamide/lacidipine/valsartan/metoprolol CR/XL, hydro-
chlorothiazide/verapamil/ramipril/bisoprolol, and chlor-
thalidon/diltiazem/perindopril/metoprolol. Only among 
physicians < 29 years of age, the regimen that included 
furosemide was not the most frequently chosen option, 
second to the regimen that included torasemide (40.7% vs. 
51.9%). Diabetologists, in contrast to all other specialists, 
preferred the regimen that included indapamide (50%). 
Suggested treatment options depending on specialization 
are shown in Figure 8.
Discussion
The new PTNT guidelines released in 2015 introduced 
a number of changes compared to both the previous 
Figure 7. Treatment regimen in elderly patients with isolated systo-
lic hypertension depending on physician’s gender; ACE — angioten-
sin-converting enzyme
Figure 8. Suggested treatment options for resistant hypertension 
depending on specialization; CR — controlled-release; XL — exten-
ded-release
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2011 edition and the European guidelines [7]. The current 
edition highlights treatment individualization in relation to 
patient characteristics including the presence of cardio-
vascular risk factors, concomitant disease, and target 
organ damage. Modifications introduced by PTNT experts 
also abolish the concept of class effect by indicating spe-
cific preparations preferred in various clinical scenarios, as 
shown in explanations to tables summarizing the guidance 
regarding the choice of drug classes. The role of fixed-dose 
preparations in the management of hypertension has also 
been highlighted.
In the surveyed physician population, these guidelines 
were the most important source of guidance for the deci-
sions regarding antihypertensive treatment, second to the 
European guidelines only among medical professionals 
< 29 years of age, cardiologists, and hospital specialists. 
Our study findings highlight a major role of the document 
prepared by the PTNT experts in shaping the therapeutic 
attitudes of Polish physicians.
According to the 2015 PTNT guidelines, the major goal 
of therapy in hypertensive patients is to reduce mortality 
and the global risk of cardiovascular and renal complica-
tions, which may be achieved by reducing blood pressure 
to target values or as close these values as possible [7].
This goal was considered the most important by nearly 
three fourths of the participating physicians, regardless 
of their age, place of work, professional experience, spe-
cialization, and practice settings. Indeed, effective blood 
pressure reduction lowers not only cardiovascular risk 
(particularly that of acute coronary syndromes and stroke), 
but also delays progression of chronic kidney disease in 
patients with hypertension [8, 9]. A significant effect of the 
mentioned clinical conditions on patients’ quality of life 
was a likely reason why nearly one fifth of the participants 
considered protection from myocardial infarction, stroke, 
and death the most important goal of antihypertensive 
treatment.
In the part of the questionnaire that focused on thera-
peutic choices, the participating physicians were offered 
specific treatment regimens or drug combinations and were 
asked to choose the most optimal ones in their opinion. In 
patients with hypertension and diabetes, the respondents 
most frequently chose a combination of an ACE inhibitor 
and a calcium antagonist, which is considered the most 
appropriate in the guidelines due to established outcome 
benefits in the high cardiovascular risk population [10]. Of 
note, this combination was particularly often chosen by 
diabetologists. The second most popular was a combination 
of an ACE inhibitor and a vasodilating beta-blocker, chosen 
by one fourth of the respondents. Currently, we have no 
evidence of the effectiveness of beta-blockers in preventing 
complications of hypertension in diabetic patients, and 
thus PTNT recommends beta-blockers in diabetic patients 
only as third or fourth choice drugs. A beneficial effect of 
vasodilating beta-blockers (carvedilol and nebivolol) on 
metabolic parameters and endothelial function was the 
reason of their preference within the beta-blocker class by 
the PTNT experts, particularly in hypertension with conco-
mitant cardiovascular disease or diabetes [7].
A combination of an ACE inhibitor and a diuretic was 
considered best in a diabetic patient only by one tenth of 
the participating physicians, while the PTNT guidelines 
consider this combination equal to that of an ACE inhibitor 
and a calcium antagonist, although with a preference of 
a thiazide-like diuretic, indapamide, among diuretics [11]. 
The low popularity of ARB combinations among the study 
participants was likely due to perceived lower clinical bene-
fits of this drug class in diabetic patients compared to ACE 
inhibitors. Indeed, a metaanalysis that compared both drug 
classes in diabetic patients confirmed a cardioprotective 
effect of ACE inhibitors which was not seen with ARB [12].
In patients with hypertension complicated with coro-
nary artery disease, clinical decisions of the participating 
physicians mostly reflected the PTNT guidelines, although 
choices of specific therapeutic options showed variation 
in relation to age of the respondents, their place of work, 
and specialization. A large majority of the participating 
physicians chose a combination of an ACE inhibitor and 
a beta-blocker or a vasodilating beta-blocker. Of note, based 
on the results of large clinical trials, three ACE inhibitors, 
perindopril, ramipril, and zofenopril, are preferred in the 
PTNT guidelines in patients with coronary artery disease, 
while vasodilating preparations are recommended among 
beta-blockers, similarly to diabetic patients [7]. Carvedilol 
and nebivolol were particularly popular among diabetolo-
gists, while other physicians more frequently chose beta-
-blockers in general, and thus believed in a class effect.
The remaining study participants preferred adding 
a calcium antagonist to an ACE inhibitor or a beta-blocker, 
which is also appropriate according to the guidelines [7]. 
A small proportion of the respondents (about 4%) would 
choose treatment with an ACE inhibitor and a diuretic, which 
is not supported in the guidelines due to availability of other 
regimens with a more beneficial effect on outcomes [7].
In patients with hypertension and concomitant heart 
failure, more than half of the respondents would choose an 
ACE inhibitor and a vasodilating beta-blocker, and one fourth 
would choose a regimen that included an ACE inhibitor and 
an aldosterone antagonist. Based on clinical trial data, it 
should be concluded that a combination of an ACE inhibitor 
and a beta-blocker in a patient with heart failure is more 
beneficial due to a documented effect of specific beta-blo-
ckers on long-term outcomes [13]. The recommended ACE 
inhibitors are lisinopril, ramipril, zofenopril, and trandolapril, 
while the recommended beta-blockers included metoprolol 
XR/CR, bisoprolol, carvedilol, and nebivolol. According to the 
guidelines, an aldosterone antagonist should be added as 
a further step, and eplerenone is preferred.
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A combination of an ARB and a diuretic would be 
chosen by less than 10% of the participating physicians. 
Angiotensin receptor blockers may be used in patients with 
heart failure who are intolerant to ACE inhibitors, and the 
preferred drugs are candesartan and valsartan. Also one 
in ten physicians would use a dihydropyridine calcium anta-
gonist in a patient with heart failure, which is unsupported 
by the available scientific evidence.
In patients with hypertension and COPD, the most 
commonly chosen combination included an ACE inhibitor 
and a calcium antagonist (about 40% of the respondents), 
followed by a combination of an ARB and a calcium anta-
gonist (about 30% of the respondents). Indeed, dihydro-
pyridine calcium antagonists are the preferred first choice 
drugs in this patient group due to favourable safety profile. 
Among the renin-angiotensin system inhibitors, ARB are 
recommended as unlike ACE inhibitors, these drugs do 
not induce cough which might provoke bronchospasm in 
COPD patients.
One in ten physicians, including one in four diabeto-
logists, chose a combination of a calcium antagonist and 
a vasodilating beta-blocker. Such a combination is warran-
ted if other indications for a beta-blocker exist, and drugs 
with cardioselective or additional protective properties 
should be used to minimize the effect on bronchial tree 
function. It is somewhat puzzling that one in five study 
participants would choose a diuretic for the treatment of 
hypertension in a patient with COPD, which is not a prefer-
red therapy in this patient group.
According to the guidelines, in the elderly patients with 
isolated systolic hypertension, the treatment should be 
initiated with a thiazide/thiazide-like diuretic and a dihydro-
pyridine calcium antagonist, if there are no indications to 
individualize therapy otherwise. This option was chosen by 
slightly more than 30% of the study participants, while abo-
ut 40% of women and about 50% of men chose treatment 
with an ACE inhibitor combined with a diuretic or a calcium 
antagonist. According to the guidelines, renin-angiotensin 
system inhibitors are recommended as second line drugs 
when the treatment needs to be intensified. One in five 
study participants preferred a vasodilating beta-blocker 
combined with a calcium antagonist or an ACE inhibitor. 
In the elderly patients with isolated systolic hypertension, 
this combination may increase the risk of falls due to fre-
quent occurrence of orthostatic hypotension. However, the 
decision to use a beta-blocker is justified in case of such 
concomitant conditions as coronary artery disease, heart 
failure, or tachyarrhythmia.
Combination antihypertensive therapy in women of re-
productive age was controversial for the study participants. 
The most popular combination, chosen by more than one 
third of the participating physicians, included a vasodila-
ting beta-blocker and a calcium antagonist. One in ten 
physicians would choose any beta-blocker combined with 
a calcium antagonist, and another 10% would recommend 
treatment with a diuretic and a calcium antagonist. Both 
combinations are considered appropriate in the guidelines, 
but thiazide-like diuretics (chlorthalidone, indapamide) are 
preferred among diuretics.
Of interest, one in four women and one in three men 
preferred combining a calcium antagonist with a centrally 
acting drug. The latter drugs lower blood pressure by 
inhibiting vasomotor and cardiac regulatory centres in 
the brainstem [14]. On the Polish market, four centrally 
acting antihypertensive agents are available: methyldopa 
(α2-adrenergic receptor agonist), clonidine (α2-adrenergic 
and imidazole receptor agonist), and rilmenidine and mo-
xonidine (imidazole receptor agonists). Among them, only 
methyldopa is a first choice agent in pregnant women, and 
other drugs are recommended as further treatment steps 
(4th or 5th choice) due to no evidence of cardiovascular and 
mortality risk reduction in hypertensive patients.
About 10% of the respondents chose a combination of 
a diuretic and a vasodilating beta-blocker. This combination 
is considered acceptable in the guidelines but inferior to 
other combinations due to a risk of adverse effects on 
lipid and glucose metabolism and the risk of orthostatic 
hypotension.
In a young man with hypertension and hyperkinetic 
circulation inadequately controlled with monotherapy, 
three fourths of the respondents declared a choice of 
a nebivolol and zofenopril regimen. Other combinations 
of a beta-blocker and an ACE inhibitor, including bisopro-
lol/perindopril and carvedilol/quinapril, were much less 
popular. A marginal proportion of the respondents would 
choose metoprolol and quinapril or metoprolol XL/CR 
and trandolapril. Indeed, clinical study results indicate 
that nebivolol, which also releases nitric oxide, is asso-
ciated with a lower risk of erectile dysfunction compared 
to other beta-blockers [15]. In turn, zofenopril seems to 
have the most beneficial pharmakokinetic profile among 
ACE inhibitors [16]. Due to its high lipophilicity, this drug 
inhibits cardiac ACE fraction effectively and longer than 
other drug of this class, which translates into potent 
action, prolonged antihypertensive effect, and postulated 
additional cardioprotective benefits. It is also believed 
that the sulfhydryl group present in the zofenopril drug 
structure is responsible for its antioxidant properties and 
a beneficial effect on lipid profile [16]. The drug also se-
ems well tolerated [17]. In a randomized crossover study 
in healthy volunteers, zofenopril provoked cough following 
stimulation with capsaicin or citric acid significantly less 
frequently than ramipril [17].
Resistant hypertension, defined as blood pressure 
values ≥ 140/90 mmHg despite use of 3 antihypertensive 
drugs (including a diuretic), remains a common clinical 
problem in Poland. According to the 2015 PTNT guidelines, 
following exclusion of pseudoresistance and modifiable 
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causes of treatment resistance, an aldosterone antagonist 
should be added as a first step in patients who received 
the recommended three-drug combination (a renin–angio-
tensin system inhibitor, a diuretic, and a calcium inhibitor). 
Addition of a beta-blocker, preferentially with vasodilating 
properties, may also be considered.
In a situation requiring use of 4 antihypertensive drugs, 
nearly half of the respondents chose the furosemide/ 
/amlodipine/zofenopril/nebivolol combination among the 
potential combinations listed, and nearly one third chose 
the torasemide/lercanidipine/telmisartan/carvedilol com-
bination. Of note, the combination including metoprolol 
succinate (indapamide/lacidipine/valsartan/metoprolol 
CR/XL) was chosen more frequently that the combination 
that included an older metoprolol preparation (chlorthali-
don/diltiazem/perindopril/metoprolol) or the combination 
that included bisoprolol (hydrochlorothiazide/verapamil/ 
/ramipril/bisoprolol).
The responses of the surveyed physicians show a high 
position of loop diuretics (furosemide) among Polish me-
dical professionals. At the same time, the newest drug in 
this class, torasemide, with a four-fold higher potency of 
the antihypertensive effect and better safety profile (me-
tabolically neutral, lower risk of electrolyte disturbances), 
was less frequently chosen by the study participants [18].
Our study results show that compared to diltiazem 
and verapamil, dihydropyridine calcium antagonists are 
much more frequently used for the treatment of resistant 
hypertension. Extensive evidence of cardiovascular risk 
reduction with amlodipine is likely the reason why the 
combinations that included this drug were most frequently 
chosen by the study participants. Of note, however, third 
generation dihydropyridines lercanidipine and lacidipine, 
which are less popular among Polish physicians, are ex-
cellent alternatives in case of adverse effects (peripheral 
oedema) during treatment with amlodipine, as also noted 
in the newest PTNT guidelines [19].
A significantly higher popularity of the regimens in-
cluding a vasodilating beta-blocker in the treatment of 
resistant hypertension shows that Polish medical profes-
sionals are convinced of clinical benefits from the use of 
these drugs. This opinion is in agreement with the position 
of PTNT which considers nebivolol and carvedilol preferred 
among beta-blockers.
When considering the management of patients with 
resistant hypertension, the role of fixed-dose combinations 
should not be neglected. Currently, Polish physicians may 
choose among six two-drug combinations and two three-
-drug combinations (perindopril/indapamide/amlodipine 
and valsartan/hydrochlorothiazuide/amlodipine), the use 
of which may improve treatment effectiveness. In addition, 
the results of a recent pharmacoeconomic analysis show 
that the use of fixed-dose combinations is associated 
not only with health benefits (a higher number of quality-
-adjusted life days) but also significant financial benefits, 
both for the public payer and the patient [20].
Study limitations
When interpreting the reported study results, it should 
be remembered that the study group included only those 
physicians who responded to the survey. It may be suspec-
ted that medical professionals who agreed to participate 
were also likely to increase their knowledge actively, were 
familiar with the 2015 PTNT guidelines, published 2 months 
before the study initiation, and had their own opinion on 
new antihypertensive medications, based on the available 
clinical study results and the marketing activity of the phar-
maceutical companies. The results regarding the choice of 
treatment regimens and specific medications within a class 
reflected suggestions offered in the survey, from which the 
physicians chose the most optimal combinations of drug 
classes and/or preparations in their opinion.
The correspondence nature of the survey allowed 
responses to be made based on other sources than per-
sonal knowledge and clinical experience. We are unable to 
exclude that the declared responses were changed after 
discussion with peers or consulting medical literature.
Finally, the structure of the study group that included 
three times more physicians working in outpatient settings 
than in hospital settings, does not allow extending the con-
clusions made to both physician populations. In addition, 
a marginal proportion of diabetologists participating in the 
study likely made our results less representative for this 
group of specialists.
Conclusions
1. Our data show a homogeneous physician attitude to-
wards antihypertensive treatment. The management was 
mostly guided by the Polish PTNT guidelines or European 
ESH/ESC guidelines. 2. In hypertensive patients with con-
comitant diabetes, the most commonly indicated regimen 
included an ACE inhibitor and a calcium antagonist, and 
a combination of an ACE inhibitor and a beta-blocker or 
a vasodilating beta-blocker was most commonly chosen 
in patients with hypertension and coronary artery disease. 
The latter combination was also most frequently indicated 
in patients with hypertension complicated with heart failu-
re. In patients with COPD, the most popular combination 
included an ACE inhibitor and a calcium antagonist, while 
a combination of a diuretic and a calcium antagonist was 
most commonly indicated for the elderly patients with 
isolated systolic hypertension. Women of reproductive age 
were most likely to receive a vasodilating beta-blocker and 
a calcium antagonist, and a combination of nebivolol and 
zofenopril was suggested for young men with hyperkinetic 
circulation. 3. The most popular regimen in patients with 
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resistant hypertension included furosemide, amlodipi-
ne, zofenopril, and nebivolol, followed by torasemide, 
lercanidipine, telmisartan, and carvedilol. 4. Our results 
show clear preferences of Polish medical professionals 
regarding specific antihypertensive medications within 
drug classes. These included vasodilating beta-blockers, 
newer ACE inhibitors (zofenopril), dihydropyridine calcium 
antagonists, and loop diuretics. These preferences are 
generally in agreement with the PTNT guidelines, except for 
recommendations regarding loop diuretics, which should 
have much lower position in the antihypertensive treatment 
compared to thiazide/thiazide-like diuretics according to 
the PTNT experts.
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Streszczenie
Wstęp. Nadciśnienie tętnicze jest najczęściej występującym modyfikowalnym czynnikiem ryzyka chorób układu sercowo-
-naczyniowego i przedwczesnego zgonu w skali globalnej. Dostępność nowych preparatów hipotensyjnych o unikatowych 
właściwościach farmakologicznych zwiększa skuteczność i bezpieczeństwo leczenia nadciśnienia tętniczego. Celem 
ankietowego badania ALMONDS była identyfikacja postaw polskich lekarzy wobec nowych leków stosowanych w terapii 
nadciśnienia tętniczego, ze szczególnym uwzględnieniem opinii na temat „efektu klasy” w obrębie leków hipotensyjnych.
Materiał i metody. Badanie przeprowadzono w formie wystandaryzowanej ankiety, którą wypełniło 784 lekarzy specjali-
stów lub specjalizujących się w kardiologii, chorobach wewnętrznych, medycynie rodzinnej i diabetologii. Forma listowna 
i anonimowość kwestionariusza ankietowego pozwoliły zmaksymalizować wiarygodność uzyskanego materiału.
Wyniki. Wśród lekarzy biorących udział w badaniu dominowały kobiety; osoby w wieku 46–60 lat. Znaczący odsetek 
lekarzy uzyskał specjalizację z chorób wewnętrznych i w zawodzie pracował od ponad 20 lat. W leczeniu chorych kie-
rowano się głównie wytycznymi Polskiego Towarzystwa Nadciśnienia Tętniczego (PTNT) lub wytycznymi europejskimi 
— European Society of Hypertension (ESH)/European Society of Cardiology (ESC). W przypadku współwystępowania 
u chorych na nadciśnienie tętnicze choroby wieńcowej najczęściej sięgano po beta-adrenolityki oraz inhibitor ACE, w tym 
inhibitor ACE i wazodylatacyjny beta-adrenolityk. Połączenie to było również najczęściej wybierane u chorych z nadciś-
nieniem tętniczym powikłanym niewydolnością serca. W przypadku kobiet w wieku rozrodczym najchętniej wybierano 
wazodylatacyjny beta-adrenolityk i antagonistę wapnia, natomiast w przypadku młodych mężczyzn z objawami zespołu 
hiperkinetycznego deklarowano wybór nebiwololu i zofenoprilu. U chorych z opornym nadciśnieniem tętniczym najczęś-
ciej stosowano: furosemid/amlodipinę/zofenopril/nebiwolol. Innym często wskazywanym schematem terapeutycznym 
był: torasemid/lerkanidipina/telmisartan/karwedilol.
Wnioski. Wyniki badania wskazują na istnienie wśród polskich specjalistów wyraźnych preferencji dotyczących konkret-
nych preparatów hipotensyjnych należących do poszczególnych klas. Wśród beta-adrenolityków preferowane są leki 
o właściwościach wazodylatacyjnych, wśród inhibitorów ACE — nowsze leki, wśród antagonistów wapnia — preparaty 
dihydropirydynowe, a wśród leków moczopędnych – diuretyki pętlowe. Stanowisko to pozostaje w dużej mierze spójne 
z zaleceniami PTNT z 2015 roku.
Słowa kluczowe: nadciśnienie tętnicze, leki hipotensyjne, wytyczne, ankiety w opiece zdrowotnej
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